Cristina Montero‐Conde

Spanish National Cancer Research Centre — Spain

Medicine · Health Sciences

30h-index3.4kcitations111works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Thyroid Cancer Diagnosis and Treatment(35), Cancer, Hypoxia, and Metabolism(19), Adrenal and Paraganglionic Tumors(19), Computational Drug Discovery Methods(16), Cancer-related Molecular Pathways(16)

Publications111 total

Molecular profiling unveils genetic complexity and identifies potential new driver mechanisms in head and neck paragangliomas
Genes & Diseases·2025Open Access
Expression of Homo Sapiens (Hsa)-miR-139-5p as a Clinically Feasible Prognostic Marker for Differentiated Thyroid Cancer
Laboratory Investigation·2025Open Access
DNA Methylation Dynamics and Prognostic Implications in Metastatic Differentiated Thyroid Cancer
Thyroid·2025· 4 citedOpen Access
Identification of a novel papillary renal cell carcinoma molecular subtype characterized by HIF-pathway over-activation
2025
MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paraganglioma
Best Practice & Research Clinical Endocrinology & Metabolism·2024· 8 citedOpen Access
Expression of HSA-MIR-139-5P as a clinically feasible prognostic marker for thyroid cancer
Endocrine Abstracts·2024
MAML3-fusions modulate Vascular and Immune Tumor Microenvironment and Confer High Metastatic Risk in Pheochromocytoma and Paraganglioma
Research Square (Research Square)·2023· 1 citedOpen Access
Deubiquitinase <scp>USP9X</scp> loss sensitizes renal cancer cells to <scp>mTOR</scp> inhibition
International Journal of Cancer·2023· 18 cited
<i>DLST</i> mutations in pheochromocytoma and paraganglioma cause proteome hyposuccinylation and metabolic remodeling
Cancer Communications·2023· 10 citedOpen Access
Data from Relief of Feedback Inhibition of &lt;i&gt;HER3&lt;/i&gt; Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in &lt;i&gt;BRAF&lt;/i&gt;-Mutant Thyroid Carcinomas
2023Open Access
Supplementary Methods and References from Relief of Feedback Inhibition of &lt;i&gt;HER3&lt;/i&gt; Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in &lt;i&gt;BRAF&lt;/i&gt;-Mutant Thyroid Carcinomas
2023Open Access
Supplementary Methods and References from Relief of Feedback Inhibition of &lt;i&gt;HER3&lt;/i&gt; Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in &lt;i&gt;BRAF&lt;/i&gt;-Mutant Thyroid Carcinomas
2023Open Access
Supplementary Figure S5 from Relief of Feedback Inhibition of &lt;i&gt;HER3&lt;/i&gt; Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in &lt;i&gt;BRAF&lt;/i&gt;-Mutant Thyroid Carcinomas
2023Open Access
Supplementary Figure S2 from Relief of Feedback Inhibition of &lt;i&gt;HER3&lt;/i&gt; Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in &lt;i&gt;BRAF&lt;/i&gt;-Mutant Thyroid Carcinomas
2023Open Access
Supplementary Figure S3 from Relief of Feedback Inhibition of &lt;i&gt;HER3&lt;/i&gt; Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in &lt;i&gt;BRAF&lt;/i&gt;-Mutant Thyroid Carcinomas
2023Open Access
Supplementary Figure S5 from Relief of Feedback Inhibition of &lt;i&gt;HER3&lt;/i&gt; Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in &lt;i&gt;BRAF&lt;/i&gt;-Mutant Thyroid Carcinomas
2023Open Access
Supplementary Figure S2 from Relief of Feedback Inhibition of &lt;i&gt;HER3&lt;/i&gt; Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in &lt;i&gt;BRAF&lt;/i&gt;-Mutant Thyroid Carcinomas
2023Open Access
Supplementary Figure S7 from Relief of Feedback Inhibition of &lt;i&gt;HER3&lt;/i&gt; Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in &lt;i&gt;BRAF&lt;/i&gt;-Mutant Thyroid Carcinomas
2023Open Access
Supplementary Figure S4 from Relief of Feedback Inhibition of &lt;i&gt;HER3&lt;/i&gt; Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in &lt;i&gt;BRAF&lt;/i&gt;-Mutant Thyroid Carcinomas
2023Open Access
Data from Relief of Feedback Inhibition of &lt;i&gt;HER3&lt;/i&gt; Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in &lt;i&gt;BRAF&lt;/i&gt;-Mutant Thyroid Carcinomas
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Mercedes Robledo(44), Alberto Cascón(36), Cristina Rodríguez‐Antona(35), Rocío Letón(28), Luis J. Leandro‐García(21), Bruna Calsina(16), Juan María Roldán‐Romero(15), Iñigo Landa(13), María Santos(12), Sergio Ruiz‐Llorente(11), María Currás-Freixes(11), Ángel M. Martínez‐Montes(11), Susanna Leskelä(10), Lucía Inglada‐Pérez(10), Javier Lanillos(10), Cristina Álvarez‐Escolá(9), Eduardo Caleiras(9), María Monteagudo(9), Elena López‐Jiménez(8), Guillermo Pita(8)